Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status

Respir Investig. 2013 Mar;51(1):46-8. doi: 10.1016/j.resinv.2012.12.001. Epub 2013 Feb 12.

Abstract

Crizotinib-an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-is effective in non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-positive lung adenocarcinoma who was administered crizotinib via nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes, with positive results. This case indicates that patients with ALK-positive NSCLC may successfully be treated with crizotinib via nasogastric or PEG tubes. This approach can even be used as a salvage treatment in patients with poor prognoses.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Administration, Oral
  • Aged
  • Anaplastic Lymphoma Kinase
  • Crizotinib
  • Enteral Nutrition
  • Female
  • Gastroscopy
  • Gastrostomy / methods*
  • Gene Expression
  • Gene Rearrangement / genetics*
  • Humans
  • Intubation, Gastrointestinal*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Molecular Targeted Therapy*
  • Oncogene Proteins, Fusion*
  • Prognosis
  • Protein Kinase Inhibitors / administration & dosage*
  • Pyrazoles / administration & dosage*
  • Pyridines / administration & dosage*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Salvage Therapy*

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases